Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 9, 2013, Pages 1551-1562

  Vaeteewoottacharn, Kulthida ^a,b   Kariya, Ryusho ^a   Matsuda, Kouki ^a   Taura, Manabu ^a   Wongkham, Chaisiri ^b   Wongkham, Sopit ^b   Okada, Seiji ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Apoptosis; Bile duct cancer; Bortezomib; Cholangiocarcinoma; ER stress; Proteasome inhibitor

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ACTIVATING TRANSCRIPTION FACTOR 6; BORTEZOMIB; CASPASE; CASPASE 12; CASPASE 3; CASPASE 4; CASPASE 8; CASPASE 9; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PROTEASOME; PROTEASOME INHIBITOR; TETRAZOLIUM; X BOX BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; BINDING ASSAY; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME SUBSTRATE; FASCIOLA HEPATICA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REPORTER GENE; TUMOR GENE; UNFOLDED PROTEIN RESPONSE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BLOTTING, WESTERN; BORONIC ACIDS; CELL PROLIFERATION; CHOLANGIOCARCINOMA; ENDOPLASMIC RETICULUM STRESS; HUMANS; JANUS KINASE 3; LUCIFERASES; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TRANSCRIPTION FACTOR CHOP; TUMOR CELLS, CULTURED; UNFOLDED PROTEIN RESPONSE;

EID: 84882735039     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1473-6     Document Type: Article

References (49)

1. An J, Sun Y, Fisher M, Rettig MB (2004) Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 18(10):1699-1704. doi: 10.1038/sj.leu.2403460 (Pubitemid 39386350)
2. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS (2012) Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142(4):1021-1031. doi: 10.1053/j.gastro.2011.12.005
3. Andrews NC, Faller DV (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19(9):2499
4. Baradari V, Hopfner M, Huether A, Schuppan D, Scherubl H (2007) Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol 13(33):4458-4466 (Pubitemid 47412408)
5. Bonifacino JS, Weissman AM (1998) Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu Rev Cell Dev Biol 14:19-57. doi: 10.1146/annurev.cellbio.14.1.19 (Pubitemid 29001448)
6. Calvaruso G, Giuliano M, Portanova P, De Blasio A, Vento R, Tesoriere G (2006) Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8. Mol Cell Biochem 287(1-2):13-19. doi: 10.1007/s11010-005-9016-3 (Pubitemid 44057388)
7. Davenport EL, Moore HE, Dunlop AS, Sharp SY, Workman P, Morgan GJ, Davies FE (2007) Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 110(7):2641-2649. doi: 10.1182/blood-2006-11-053728 (Pubitemid 47523188)
8. DuRose JB, Tam AB, Niwa M (2006) Intrinsic capacities of molecular sensors of the unfolded protein response to sense alternate forms of endoplasmic reticulum stress. Mol Biol Cell 17(7):3095-3107. doi: 10.1091/mbc.E06-01-0055 (Pubitemid 43993512)
9. Fels DR, Ye J, Segan AT, Kridel SJ, Spiotto M, Olson M, Koong AC, Koumenis C (2008) Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res 68(22):9323-9330. doi: 10.1158/0008-5472.CAN-08-2873
10. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674. doi: 10.1016/j.cell.2011.02.013
11. Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A (2009) Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 625(1-3):234-246. doi: 10.1016/j.ejphar.2009.06.064
12. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61(7):3071-3076 (Pubitemid 32691956)
13. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114(5):1046-1052. doi: 10.1182/blood-2009-01-199604
14. Hui B, Shi YH, Ding ZB, Zhou J, Gu CY, Peng YF, Yang H, Liu WR, Shi GM, Fan J (2012) Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma. Cancer 118(22):5560-5571. doi: 10.1002/cncr.27586
15. Iwawaki T, Akai R (2006) Analysis of the XBP1 splicing mechanism using endoplasmic reticulum stress-indicators. Biochem Biophys Res Commun 350(3):709-715. doi: 10.1016/j.bbrc.2006.09.100 (Pubitemid 44547905)
16. Iwawaki T, Akai R, Kohno K, Miura M (2004) A transgenic mouse model for monitoring endoplasmic reticulum stress. Nat Med 10(1):98-102. doi: 10.1038/nm970 (Pubitemid 38524705)
17. Jia L, Gopinathan G, Sukumar JT, Gribben JG (2012) Blocking autophagy prevents bortezomib-induced NF-kappaB activation by reducing I-kappaBalpha degradation in lymphoma cells. PLoS ONE 7(2):e32584. doi: 10.1371/journal.pone. 0032584
18. Jinawath N, Chamgramol Y, Furukawa Y, Obama K, Tsunoda T, Sripa B, Pairojkul C, Nakamura Y (2006) Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology 44(4):1025-1038. doi: 10.1002/hep.21330 (Pubitemid 46489566)
19. Kawabata S, Gills JJ, Mercado-Matos JR, Lopiccolo J, Wilson W 3rd, Hollander MC, Dennis PA (2012) Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death Dis 3:e353. doi: 10.1038/cddis.2012.87
20. Lai E, Teodoro T, Volchuk A (2007) Endoplasmic reticulum stress: signaling the unfolded protein response. Physiology 22:193-201. doi: 10.1152/physiol.00050.2006
21. Li C, Chen S, Yue P, Deng X, Lonial S, Khuri FR, Sun SY (2010) Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem 285(21):16096-16104. doi: 10.1074/jbc.M109.072694
22. Ma Y, Hendershot LM (2004) The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 4(12):966-977. doi: 10.1038/nrc1505 (Pubitemid 39626220)
23. Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S (2008) Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 6(8):1356-1364. doi: 10.1158/1541-7786.MCR-08-0108
24. Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D, Harris AL (2009) The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res 69(10):4415-4423. doi: 10.1158/0008-5472.CAN-08-2839
25. Morise Z, Sugioka A, Tokoro T, Tanahashi Y, Okabe Y, Kagawa T, Takeura C (2010) Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol 2(2):58-64. doi: 10.4254/wjh.v2.i2.58
26. Nakata W, Hayakawa Y, Nakagawa H, Sakamoto K, Kinoshita H, Takahashi R, Hirata Y, Maeda S, Koike K (2011) Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer. Int J Oncol 39(6):1529-1536. doi: 10.3892/ijo.2011.1141
27. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J, McConkey DJ (2002) Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1(14):1243-1253
28. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr, Huang P, Abbruzzese JL, McConkey DJ (2005) Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65(24):11658-11666. doi: 10.1158/0008-5472.CAN-05-2370 (Pubitemid 41821726)
29. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23(4):676-684. doi: 10.1200/JCO.2005.02.050 (Pubitemid 46237441)
30. Oikawa D, Kitamura A, Kinjo M, Iwawaki T (2012) Direct association of unfolded proteins with mammalian ER stress sensor, IRE1beta. PLoS ONE 7(12):e51290. doi: 10.1371/journal.pone.0051290
31. Okada S, Harada H, Ito T, Saito T, Suzu S (2008) Early development of human hematopoietic and acquired immune systems in new born NOD/Scid/Jak3null mice intrahepatic engrafted with cord blood-derived CD34 + cells. Int J Hematol 88(5):476-482. doi: 10.1007/s12185-008-0215-z
32. Palmer WC, Patel T (2012) Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 57(1):69-76. doi: 10.1016/j.jhep.2012.02.022
33. Patel T (2011) Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol 8(4):189-200. doi: 10.1038/nrgastro.2011.20
34. Richardson PG, Mitsiades C (2005) Bortezomib: proteasome inhibition as an effective anticancer therapy. Future Oncol 1(2):161-171. doi: 10.1517/14796694.1.2.161
35. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487-2498. doi: 10.1056/NEJMoa043445 (Pubitemid 41007864)
36. Rzymski T, Milani M, Singleton DC, Harris AL (2009) Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 8(23):3838-3847
37. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906-917. doi: 10.1056/NEJMoa0801479
38. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR (2000) Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404(6779):770-774. doi: 10.1038/35008096 (Pubitemid 30212405)
39. Seubwai W, Vaeteewoottacharn K, Hiyoshi M, Suzu S, Puapairoj A, Wongkham C, Okada S, Wongkham S (2010) Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF-kappaB. Cancer Sci 101(7):1590-1595. doi: 10.1111/j.1349-7006.2010.01572.x
40. Singal AK, Vauthey JN, Grady JJ, Stroehlein JR (2011) Intra-hepatic cholangiocarcinoma-frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center. J Cancer Res Clin Oncol 137(7):1071-1078. doi: 10.1007/s00432-010-0971-z
41. Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripa C, Miwa M (2005) Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol 11(22):3392-3397 (Pubitemid 40873244)
42. Sripa B, Thinkhamrop B, Mairiang E, Laha T, Kaewkes S, Sithithaworn P, Periago MV, Bhudhisawasdi V, Yonglitthipagon P, Mulvenna J, Brindley PJ, Loukas A, Bethony JM (2012) Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by Opisthorchis viverrini. PLoS Negl Trop Dis 6(5):e1654. doi: 10.1371/journal.pntd.0001654
43. Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24(3):148-154 (Pubitemid 19163397)
44. Ustundag Y, Bronk SF, Gores GJ (2007) Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells. World J Gastroenterol 13(6):851-857 (Pubitemid 46470294)
45. von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismuller TJ, Wedemeyer H, Manns MP, Greten TF, Malek NP (2011) Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol 46(9):1092-1098. doi: 10.3109/00365521.2011.589472
46. Weissman AM, Shabek N, Ciechanover A (2011) The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nat Rev Mol Cell Biol 12(9):605-620. doi: 10.1038/nrm3173
47. Wu WK, Cho CH, Lee CW, Wu K, Fan D, Yu J, Sung JJ (2010) Proteasome inhibition: A new therapeutic strategy to cancer treatment. Cancer Lett 293(1):15-22. doi: 10.1016/j.canlet.2009.12.002
48. Xu L, Su L, Liu X (2012) PKCdelta regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells. Mol Cancer Ther 11(10):2174-2182. doi: 10.1158/1535-7163.MCT-12-0602
49. Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S (2008) Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer 7:40. doi: 10.1186/1476-4598-7-40 (Pubitemid 351790219)